Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Cullinan Therapeutics, Inc. (CGEM) AI Forecast

Our AI ranks Cullinan Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$CGEM Bullish Signal Full forecast available
Sign Up Free

Cullinan Therapeutics, Inc. (CGEM) Stock Forecast Sept. 21, 2026

Cullinan Therapeutics, Inc. (CGEM) AI Stock Price Forecast & Investment Analysis

Cullinan Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Cullinan Therapeutics, Inc. (CGEM) - Comprehensive Stock Analysis & Investment Research

Deep dive into Cullinan Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 21, 2026 (UTC)

Cullinan Therapeutics, Inc. Investment Summary

When evaluating whether Cullinan Therapeutics, Inc. (CGEM) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Cullinan Therapeutics, Inc. (CGEM) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $1 billion, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Cullinan Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Cullinan Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Cullinan Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Cullinan Therapeutics, Inc.

Sign Up Free
Corporate Identity

Cullinan Therapeutics, Inc. (Stock Symbol: CGEM) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Cullinan Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Cullinan Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Cullinan Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Cullinan Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Cullinan Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Cullinan Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Cullinan Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Cullinan Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Cullinan Therapeutics, Inc.'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Cullinan Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Cullinan Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 8.42 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Cullinan Therapeutics, Inc. (CGEM) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cullinan Therapeutics, Inc. stock analysis.

Deep dive into Cullinan Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Cullinan Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Cullinan Therapeutics, Inc.:

P/B Ratio 4.27x
Market Cap $1.37B
Book Value/Share $5.00
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Cullinan Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Cullinan Therapeutics, Inc.: An ROE of -63.6% indicates room for improvement in shareholder value creation.

ROE -63.6%
ROA -56.3%
ROIC -68.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Cullinan Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Cullinan Therapeutics, Inc.: A current ratio of 8.42 indicates strong liquidity.

Current Ratio 8.42x
D/E Ratio 0.13x
Financial Leverage 1.13x
Interest Coverage -1019.0x
Working Capital $301M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Cullinan Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Cullinan Therapeutics, Inc.:

Operating Cash Flow -$159M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Cullinan Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Cullinan Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Cullinan Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Cullinan Therapeutics, Inc.:

Income Statement
Operating Income -$221M
Net Income -$204M
R&D Expense $171M
Balance Sheet Highlights (USD millions)
Total Current Assets $342M (94.0% of assets)
Cash & Short-term Investments $79M (21.6% of assets)
Total Liabilities $42M (11.6% of assets)
Short-term Debt $37M (10.1% of assets)
Dividend & Shareholder Information
Shares Outstanding 64M

Latest Cullinan Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Cullinan Therapeutics, Inc. (CGEM) stock price and investment outlook.

📰 Loading...

Where CGEM sits on the market map

Explore the map →

Cullinan Therapeutics, Inc. Industry Peers - Biological Products, (No Diagnostic Substances)

Companies classified under the same SEC industry code as Cullinan Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
CGEM ██% $1.37B x 4.3x
AMGN ██% $212.55B 24.3x 18.2x
GILD ██% $186.13B x 15.7x
MRNA ██% $61.50B x 9.1x
ARGX ██% $61.15B x x
RVMD ██% $40.93B x 15.7x
BIIB ██% $32.34B 23.6x 1.7x
BNTX ██% $24.78B x x
MESO ██% $19.62B x x
NBIX ██% $14.86B 21.1x 4.0x
EXEL ██% $14.18B x 7.7x
HALO ██% $12.76B 30.9x 88.9x
TECH ██% $11.35B 62.4x 5.4x
TWST ██% $10.47B x 23.5x
APGE ██% $10.22B x x
RGEN ██% $9.98B 240.3x 4.7x
KRYS ██% $9.97B 41.3x 7.3x
KYMR ██% $9.79B x 6.5x
QGEN ██% $9.40B x 2.5x
IBRX ██% $8.99B x x
PCVX ██% $8.65B x 3.1x
IMVT ██% $7.63B x 10.4x
CGON ██% $6.94B x 6.7x
SRRK ██% $5.68B x 22.4x
CRSP ██% $5.64B x 3.2x
IOVA ██% $4.64B x 6.3x
ADPT ██% $4.45B x 31.1x
RLAY ██% $4.13B x 4.6x
DBVT ██% $3.58B x 21.2x
TARS ██% $3.43B x 9.9x
DNLI ██% $3.27B x 3.9x
BEAM ██% $2.61B x 2.4x
BCRX ██% $2.24B x x
SCNI ██% $2.16B x 275.4x
ADMA ██% $2.13B 12.6x 5.2x
KOD ██% $2.06B x 33.7x
RXRX ██% $2.05B x 2.2x
VCEL ██% $2.05B 84.6x 5.5x
ALVO ██% $1.83B x x
VIR ██% $1.79B x 1.8x
COAG ██% $1.77B x 3.9x
NVAX ██% $1.67B x x
IMCR ██% $1.65B x 3.9x
TSHA ██% $1.64B x 4.2x
MGTX ██% $1.27B 16.1x 5.9x
VOR ██% $1.27B x x
MAZE ██% $1.25B x 2.8x
REPL ██% $1.23B x 11.7x
JATT ██% $1.17B x 6.0x
ODTX ██% $1.17B x 2.8x
IMTX ██% $1.16B x x
VALN ██% $1.14B x x
GLUE ██% $1.03B x 2.1x
SLDB ██% $955M x 2.6x
SANA ██% $928M x 6.0x
CADL ██% $858M x 6.8x
FDMT ██% $841M x 2.1x
AURA ██% $660M x 2.1x
ALLO ██% $584M x 1.3x
PRME ██% $566M x 14.2x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Cullinan Therapeutics, Inc. Stock Forecast

How accurate are Cullinan Therapeutics, Inc. stock predictions?

A per-ticker accuracy statistic for CGEM is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Cullinan Therapeutics, Inc. stock price forecasts?

Our analysis considers Cullinan Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Cullinan Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Cullinan Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Cullinan Therapeutics, Inc. forecasts updated?

Cullinan Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 21, 2026.

Want a simpler view of Cullinan Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...